In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific Symbiot

This article was originally published in The Gray Sheet

Executive Summary

Covered stent system for saphenous vein graft disease debuts in Europe following CE mark approval. The self-expanding nitinol stent, which is encased in a thin, porous ePTFE polymer membrane, decreases plaque embolization during the stenting procedure and reduces restenosis, according to the firm. Symbiot III, a 700-patient, multicenter, U.S. randomized clinical trial is underway, and FDA approval is expected in early 2004...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts